Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00795262 · ClinicalTrials.gov registry record · NA
Effects of Quinapril 40 mg With Alpha Lipoic Acid or Placebo on Diabetes and Hypertension
A NA study of Hypertension and Diabetes, sponsored by InVasc Therapeutics.
- Completed
- Registry status
- NA
- Development phase
- 23
- Enrollment target
- 1
- Study location
NCT00795262: Completed NA study of Hypertension and Diabetes, sponsored by InVasc Therapeutics.
NCT00795262 is a NA study of Hypertension and Diabetes that has completed, run by InVasc Therapeutics. The registered enrollment target is 23 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00795262, a NA study of Hypertension and Diabetes, has completed, sponsored by InVasc Therapeutics.
- COMPLETED
- Registry status
- NA
- Development phase
- 23 participants
- Enrollment target
- 1
- Study location
Study Summary
We will evaluate the combination of quinapril and alpha lipoic acid in patients with diabetes mellitus and hypertension. We will determine whether the combination of quinapril and lipoic acid as compared to quinapril and placebo provides benefit on systemic blood pressure and proteinuria.
Conditions Studied
Interventions
- DRUG Quinapril (Accupril) plus Alpha Lipoic Acid
- DRUG accupril, placebo
- DRUG accupril, alpha lipoic acid
Study Locations (1)
Georgia
- Atlanta Vascular Research Foundation - Tucker
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2008-07 |
| Est. Completion | 2009-07 |
| Phase | NA |
What the finished NCT00795262 record still lists
NCT00795262 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Hypertension appearing as the primary indexed condition, and to 3 interventions - of which Quinapril (Accupril) plus Alpha Lipoic Acid is the first listed.
NCT00795262 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT00795262 about?
NCT00795262 is a clinical study titled "Effects of Quinapril 40 mg With Alpha Lipoic Acid or Placebo on Diabetes and Hypertension". We will evaluate the combination of quinapril and alpha lipoic acid in patients with diabetes mellitus and hypertension. We will determine whether the combination of quinapril and lipoic acid as compared to quinapril and placebo provides benefit on systemic blood pressure and proteinuria.
What is the current status of trial NCT00795262?
This trial is currently completed. It is a NA study. The enrollment target is 23 participants. The study started on 2008-07. Estimated completion is 2009-07.
What conditions does trial NCT00795262 study?
This clinical trial studies the following conditions: Hypertension, Diabetes.
What interventions are being tested in trial NCT00795262?
The interventions under investigation include: Quinapril (Accupril) plus Alpha Lipoic Acid (DRUG), accupril, placebo (DRUG), accupril, alpha lipoic acid (DRUG).
Who is sponsoring clinical trial NCT00795262?
This trial is sponsored by InVasc Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00795262 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00795262's enrollment target sits among peer trials
23 434th of 470 higher than 34 of 470 other Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ketone Ester And Salt (KEAS) in Older Adults
RECRUITING · NA
-
How a Mediterranean Diet With Potatoes Impacts Heart and Metabolic Health in Adults With Pre-Diabetes
RECRUITING · NA
-
Conical Forearm and Cylindrical Upper Arm Non-Invasive Blood Pressure (NIBP) Measurements in Pregnant Patients
RECRUITING · NA
-
Comparing Healthcare Visit Recording and Open Notes to Improve Chronic iLlness Care Experience in Older Adults
RECRUITING · NA
-
Early Time-Restricted Eating in Older Adults With Hypertension
RECRUITING · NA
-
Targeting Metabolic Syndrome From the Emergency Department Through Mixed-Methods: Pilot Trial
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04796012 · 23 participants · Phase 1
VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia